A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00649415
First received: March 28, 2008
Last updated: April 7, 2008
Last verified: March 2008
  Purpose

To compare the analgesic efficacy, safety, and tolerability of valdecoxib versus piroxicam in subjects with moderate to severe menstrual cramping pain associated with primary dysmenorrhea.


Condition Intervention Phase
Dysmenorrhea
Drug: piroxicam
Drug: valdecoxib
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg BID, PRN In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Total pain relief were calculated as the summed weighted pain releif scores [ Time Frame: 8 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • adverse events [ Time Frame: approximately 5 days after treated cycle ] [ Designated as safety issue: Yes ]
  • laboratory analyses [ Time Frame: screening ] [ Designated as safety issue: Yes ]
  • Subjects' global evaluation of the study drug [ Time Frame: 8 hours and 72 hours ] [ Designated as safety issue: No ]
  • Summed pain intensity difference [ Time Frame: 8 hours ] [ Designated as safety issue: No ]
  • Percent of subjects who took rescue medication [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
  • Percent of subjects who took the second dose of study medication [ Time Frame: 72 hours ] [ Designated as safety issue: No ]

Enrollment: 154
Study Start Date: January 2003
Study Completion Date: July 2003
Arms Assigned Interventions
Active Comparator: Arm 1 Drug: piroxicam
piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
Active Comparator: Arm 2 Drug: valdecoxib
valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle

  Eligibility

Ages Eligible for Study:   18 Years to 44 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of primary dysmenorrhea with moderate to severe menstrual cramping pain for which the patient took analgesic medication for at least three of six previous menstrual cycles before enrollment
  • Subjects were to have been in good health and were to have had a complete physical exam (including a pap smear and an endovaginal or pelvic ultrasound, unless the subject had had these examinations performed within 6 months prior to the Screening Visit and the results were normal) prior to inclusion

Exclusion Criteria:

  • Subjects who were pregnant, lactating, breastfeeding or not using adequate methods of birth control
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00649415

Locations
Brazil
Pfizer Investigational Site
Salvador, Bahia, Brazil
Pfizer Investigational Site
Goiania, Goias, Brazil
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30130-100
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30130-110
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil, 90610-000
Pfizer Investigational Site
Rio De Janeiro, RJ, Brazil, 20551-030
Pfizer Investigational Site
Porto Alegre, RS, Brazil
Pfizer Investigational Site
São Paulo, SP, Brazil
Pfizer Investigational Site
Sao Paulo, Brazil
Pfizer Investigational Site
São Paulo, Brazil, 04062-003
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00649415     History of Changes
Other Study ID Numbers: VALA-0513-137, A3471081
Study First Received: March 28, 2008
Last Updated: April 7, 2008
Health Authority: Brazil: National Health Surveillance Agency

Additional relevant MeSH terms:
Dysmenorrhea
Menstruation Disturbances
Pathologic Processes
Pelvic Pain
Pain
Signs and Symptoms
Piroxicam
Valdecoxib
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors

ClinicalTrials.gov processed this record on August 21, 2014